NTBLQ (Notable Labs) EV-to-EBIT: 0.00 (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Notable Labs EV-to-EBIT?

Notable Labs NTBLQ -90.00% EV-to-EBIT is 0.00 as of Aug. 31, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Notable Labs's Enterprise Value is $0.00 Mil. Notable Labs's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-9.22 Mil. Therefore, Notable Labs's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Notable Labs's EV-to-EBIT or its related term are showing as below:

NTBLQ's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 15.95
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Notable Labs's Enterprise Value for the quarter that ended in Jun. 2024 was $3.77 Mil. Notable Labs's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-9.22 Mil. Notable Labs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -244.21%.

Notable Labs  (OTCPK:NTBLQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Notable Labs's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-9.218/3.7746474
=-244.21 %

Notable Labs's Enterprise Value for the quarter that ended in Jun. 2024 was $3.77 Mil.
Notable Labs's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs EV-to-EBIT Related Terms

Notable Labs EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Notable Labs's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs EV-to-EBIT Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
0.00 0.00 -0.50

Notable Labs Quarterly Data
Dec21 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial 0.00 0.00 -0.50 -1.42 -0.41

NTBLQ vs VRTX, REGN, ALNY: EV-to-EBIT Comparison

For the Biotechnology subindustry, Notable Labs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Notable Labs EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Notable Labs's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Notable Labs's EV-to-EBIT falls into.


Notable Labs EV-to-EBIT Calculation

Notable Labs's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-9.218
=0.00

Notable Labs's current Enterprise Value is $0.00 Mil.
Notable Labs's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.00 mean?
Notable Labs (NTBLQ) has a EV-to-EBIT of 0.00 as of Aug. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Notable Labs and its competitors.
Is Notable Labs' EV-to-EBIT too high?
Notable Labs' current EV-to-EBIT is 0.00.
How does Notable Labs' EV-to-EBIT compare to VRTX and REGN?
Notable Labs' EV-to-EBIT of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.95, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Notable Labs and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Notable Labs's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Notable Labs stock overvalued right now?
Notable Labs (NTBLQ) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Notable Labs (NTBLQ), the current EV-to-EBIT is 0.00 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Notable Labs Business Description

Address 320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.